<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Brivanib inhibits VEGFR — pCite</title>
<link rel="stylesheet" href="../css/style.css">
</head>
<body>
<header>
  <h1><a href="../index.html">pCite</a></h1>
  <nav><a href="../index.html">Search</a><a href="../corpus.html">Corpus</a></nav>
</header>

<p class="section-label">CLAIM</p>
<hr class="section-rule">
<div class="triple">
  <strong>Brivanib</strong>
  <span class="pred">&mdash;inhibits&rarr;</span>
  <strong>VEGFR</strong>
</div>
<div class="entity-id">CHEBI:CHEBI:72537 &nbsp;&middot;&nbsp; UNKNOWN:VEGFR</div>

<p class="section-label">VALIDATION</p>
<hr class="section-rule">
<div class="val-bar" style="--pct:0%;--color:#d62728"></div>
<div class="stat-row">
  <span>Class: AI Generated (0.01)</span>
  <span>Replicated: 1 paper</span>
  <span>Score: 0.08<span class="score-tip"><span class="tip-icon">&nbsp;&#9432;</span><span class="tip-text">Score = &Sigma; incoming citation weights. Each citation is weighted by the validation class of the source claim (Physical 10.0 &middot; Curated 0.5 &middot; AI 0.01) multiplied by the citation type (Replicates 1.5 &middot; Supports 1.0 &middot; Contradicts 0.8). A score of 364 means this claim received strong physical-tier citation support.</span></span></span>
</div>

<p class="section-label">SCORE BREAKDOWN</p>
<hr class="section-rule">
<div class="score-breakdown">Base weight: 0.01 (AI Generated, 1 paper)<br>Score from 8 citations: <strong>0.08</strong><br><span style="color:#888">1&times; extends (+0.01) &middot; 6&times; supports (+0.06) &middot; 1&times; applies (+0.01)</span></div>


<p class="section-label">EVIDENCE CHAIN &middot; 1 source</p>
<hr class="section-rule">
<div class="evidence-row"><span class="evidence-dot" style="background:#d62728" title="AI Generated"></span><span>AI Generated</span><a href="https://doi.org/10.1002/cam4.6248">10.1002/cam4.6248</a></div>


<p class="section-label">CITATIONS RECEIVED &middot; 8 total</p>
<hr class="section-rule">
<div class="cite-bar"><span style="width:70px;text-align:right">Replicates</span><span class="cite-bar-fill" style="width:0px"></span><span>0</span></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Supports</span><span class="cite-bar-fill" style="width:100px"></span><span>6</span><span class="cite-subtotal">&middot; +0.06</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Brivanib — causes → Hypertension</span><span class="cite-claim-weight">+0.01</span><a href="../claim/6a7fae877f755fc9.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Brivanib-induced hypertension — predicts → Overall survival in metastatic colorectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/b1712dd89d9a1101.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Lysophosphatidylcholine (LPC) — distinguishes → Brivanib-induced hypertension</span><span class="cite-claim-weight">+0.01</span><a href="../claim/82a3bed01a275c34.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Sphingomyelin — distinguishes → Brivanib-induced hypertension</span><span class="cite-claim-weight">+0.01</span><a href="../claim/af14263ea5d6b85e.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Phosphatidylcholine — distinguishes → Brivanib-induced hypertension</span><span class="cite-claim-weight">+0.01</span><a href="../claim/5055fcae71924d56.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Brivanib — treats → Metastatic colorectal cancer</span><span class="cite-claim-weight">+0.01</span><a href="../claim/2a19e047075cea7a.html">view &rarr;</a></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Contradicts</span><span class="cite-bar-fill" style="width:0px"></span><span>0</span></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Extends</span><span class="cite-bar-fill" style="width:17px"></span><span>1</span><span class="cite-subtotal">&middot; +0.01</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Brivanib — inhibits → FGFR</span><span class="cite-claim-weight">+0.01</span><a href="../claim/89abfcc587d15524.html">view &rarr;</a></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Applies</span><span class="cite-bar-fill" style="width:17px"></span><span>1</span><span class="cite-subtotal">&middot; +0.01</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#d62728"></span><span class="cite-claim-triple">Lysophosphatidylcholine (LPC) — is_biomarker_for → Brivanib-induced hypertension</span><span class="cite-claim-weight">+0.01</span><a href="../claim/9bb697aef1f62008.html">view &rarr;</a></div>


<p class="section-label">IDENTIFIERS</p>
<hr class="section-rule">
<table class="id-table">
<tr><td>Claim ID</td><td><code>b1f45dd778144156</code></td></tr>
<tr><td>Subject URI</td><td><a href="https://identifiers.org/CHEBI:CHEBI:72537">CHEBI:CHEBI:72537</a></td></tr>
<tr><td>Object URI</td><td><a href="https://identifiers.org/UNKNOWN:VEGFR">UNKNOWN:VEGFR</a></td></tr>
</table>
<footer>pCite — validation-weighted scientific claims</footer>
</body>
</html>
